> Bristol-Myers Squibb said the FDA granted full approval for its leukemia drug Sprycel, which the company has been marketing under accelerated approval since 2006. Report
> Pfizer won dismissal of a false-claims lawsuit that alleged it illegally boosted sales through a campaign that misled doctors about its cholesterol pill Lipitor. Report
> A growing number of hospital patients are routinely given proton pump inhibitors to prevent acid reflux, but a new study found that patients who take the drugs are at higher risk for pneumonia. Report
> Belgium's Solvay Group plans a 150 million euro offering of six-year bonds, using the proceeds to refinance short-term commercial paper. Report
> Notwithstanding the global economic crisis, India's pharmaceutical industry is expected to grow rapidly in the next few years, McKinsey & Co. said. Report
> Generics maker Teva Pharmaceutical Industries claims in a lawsuit that Amgen is using its patented invention to make the kidney disease treatment Sensipar. Report
> MAP Pharmaceuticals' experimental orally inhaled migraine drug reached all four goals of a late-stage clinical study, the company said Tuesday. Its shares more than doubled. Report
> India's Dabur is stepping up expansion in the skin care segment, on the back of its acquisition of Fem Care Pharma last year. Report
> Despite setbacks, Intercytex is working hard to stay in the game. After soaring 56 percent last week, the troubled U.K. biotech saw it shares jump again yersterday--this time 30 percent--on the news that Pfizer is among the company's suitors. Report
> In what the Washington Business Journal describes as the "end of an era," Celera is shuttering its remaining 41,000-square-foot facility in Rockville, MD and laying off 20 of its 25 local staffers. Report
> A sit-down with regulators at the FTC a few days ago left executives at CSL convinced the agency will move quickly to block its proposed $3.1 billion merger with Talecris Biotherapeutics. Report
> Impressed by new data on Cytokinetics' experimental heart failure drug, Amgen has decided to exercise its option to buy the rights to the therapy. The biotech giant-which paid $75 million for the option two years ago-will fork over an additional $50 million plus up to $600 million in milestones. Report
> A team of researchers at Oxford University say that they have refined their ability to engineer a virus that targets specific cells, offering a new approach to treating cancer and creating a new generation of vaccines for viral diseases. Report
> Francis Collins, a pioneering geneticist, is the leading candidate for the top job at the NIH, according to a report in Bloomberg. Report
And Finally... Check out the interactive map of FDA-registered facilities worldwide from in-Pharma Technologist. Report